{"preliminary_commentary":{"by_channel":{"x_thread":38,"podcast":22,"youtube":9},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06320067\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"STAMPEDE 2","nct_id":"NCT06320067","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stampede-2-nct06320067. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"STAMPEDE2","arms":[{"description":"SoC (ADT + ARPI ± docetaxel + local RT)","label":"Arm A of SABR Comparison","type":"ACTIVE_COMPARATOR"},{"description":"SoC (ADT + ARPI ± docetaxel + local RT) + SABR","label":"Arm S of SABR Comparison","type":"EXPERIMENTAL"},{"description":"SoC (ADT + ARPI ± docetaxel ± local RT)","label":"Arm A of 177Lu-PSMA-617 Comparison","type":"ACTIVE_COMPARATOR"},{"description":"SoC (ADT + ARPI ± docetaxel ± local RT) + 177Lu-PSMA-617","label":"Arm P of 177Lu-PSMA-617 Comparison","type":"EXPERIMENTAL"}],"collaborators":["Cancer Research UK","Novartis"],"completion_date":{"date":"2032-03","type":"ESTIMATED"},"conditions":["Prostate Cancer Metastatic"],"enrollment":{"count":3360,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Stereotactic Ablative Body Radiotherapy (SABR)","otherNames":["Stereotactic body radiotherapy (SBRT)"],"type":"RADIATION"},{"name":"177Lu-PSMA-617","otherNames":["Lutetium (177Lu) Vipivotide Tetraxetan","AAA617","Pluvicto"],"type":"OTHER"},{"name":"Androgen Deprivation Therapy (ADT)","otherNames":[],"type":"DRUG"},{"name":"Androgen Receptor Signalling Inhibitor (ARPI)","otherNames":[],"type":"DRUG"},{"name":"Radiotherapy to Prostate ± Pelvic Nodes","otherNames":[],"type":"RADIATION"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2025-09-26","lead_sponsor":"University College, London","official_title":"Studying Treatments in Patients Receiving Androgen Deprivation Therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and Radiation Efficacy: A 2nd Multi-arm Multi-stage Randomised Controlled Trial (STAMPEDE2).","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2031-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Final analysis for each comparison triggered when adequate number of death events have occurred in control arm of each comparison. Anticipate final reporting for OS in Comparison S: ~84 months (7 years) from FPFV, P: ~64 months (5.3 years) from FPFV."}],"references":[],"start_date":{"date":"2024-06-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT06320067"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stampede-2-nct06320067"}